simethicone profile

Simethicone: A poly(dimethylsiloxane) which is a polymer of 200-350 units of dimethylsiloxane, along with added silica gel. It is used as an antiflatulent, surfactant, and ointment base. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6433516
SCHEMBL ID	339371
MeSH ID	M0019885

Synonym
simethicone
8050-81-5
simeticone
FT-0674588
SCHEMBL339371
dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane
Q419415
DB09512

Research Excerpts

Overview

Simethicone is a common antifoaming agent that is added to endoscopic rinse solutions, but data regarding its effect on polyp detection rates is lacking. Simethicone has been implicated as a risk factor for transmission of infections due to the formation of simethicone deposits within scope channels.

Excerpt	Reference	Relevance
"Simethicone is an adjunct frequently used during bowel preparation before colonoscopy and currently there is no consensus on whether it should be recommended in standard bowel preparation. "	( Simethicone decreases bloating and improves bowel preparation effectiveness: a systematic review and meta-analysis. Dang, JT; Dang, TNT; Karmali, S; Moolla, M; Shaw, A; Sultanian, R; Tian, C, 2019)	3.4
"Simethicone (SIM) is a commonly used antifoaming agent in the clinic. "	( The Efficacy of Simethicone With Polyethylene Glycol for Bowel Preparation: A Systematic Review and Meta-Analysis. Fei, S; Li, Z; Liu, X; Yuan, M; Zhao, G, 2021)	2.41
"Simethicone is a common antifoaming agent that is added to endoscopic rinse solutions, but data regarding its effect on polyp detection rates is lacking. "	( Influence of Simethicone Added to the Rinse Water during Colonoscopies on Polyp Detection Rates: Results of an Unintended Cohort Study. Gould, K; Gururatsakul, M; Gurusamy, SR; Holtmann, GJ; Hourigan, L; Kendall, BJ; Kutyla, M; O'Connor, S; Whaley, A, 2018)	2.29
"Simethicone is an anti-foaming agent commonly used during colonoscopy. "	( The benefit of adding oral simethicone in bowel preparation regimen for the detection of colon adenoma: A systematic review and meta-analysis. Chen, TH; Hsu, MH; Huang, RY; Lee, CT; Lin, CW; Tseng, CM; Wang, WL; Yeh, JH, 2019)	2.25
"Simethicone is an antifoaming agent frequently added to endoscopic rinse solutions but has recently been implicated as a risk factor for transmission of infections due to the formation of simethicone deposits within scope channels. "	( An in vitro and clinical dose-finding study of antifoaming effects of simethicone during colonoscopy. Elson, J; Holtmann, GJ; Hourigan, LF; Kutyla, MJ; Meeusen, V; O'Connor, S; Shah, A, 2019)	2.19
"Simethicone is an inert antifoaming able to reduce bloating, abdominal discomfort. "	( A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome. Casale, C; de Vitis, I; Pistelli, R; Rapaccini, GL; Urgesi, R, 2014)	2.06
"Simethicone is a well-known emulsifying agent that has been used to improve ultrasonographic visualization."	( Factors Predictive of Improved Abdominal Ultrasound Visualization after Oral Administration of Simethicone. Biagini, MR; Casseri, T; Gabbani, T; Marsico, M, 2016)	1.37
"Simethicone is an inert, hydrophobic substance that may reduce reprocessing effectiveness."	( Simethicone residue remains inside gastrointestinal endoscopes despite reprocessing. Heymann, OL; Johnson, EA; Maust, TJ; Ofstead, CL; Shaw, MJ; Wetzler, HP, 2016)	2.6
"Simethicone is a safe and inexpensive medication that may provide anesthesiologists with an effective treatment choice for suspected postoperative abdominal discomfort in infants."	( Evaluation of simethicone for the treatment of postoperative abdominal discomfort in infants. Burke, C; D'Agostino, R; Hadden, SM; Malviya, S; Siewert, M; Tait, AR; Voepel-Lewis, TD, 1998)	2.1
"Simethicone, which is a principal ingredient in the defoaming agent used during gastroscopy, can inhibit the growth of Helicobacter pylori (MIC, 64-128 mg/l). "	( Effect of simethicone on the accuracy of the rapid urease test. Chow, SL; Kng, C; Lai, KC; Ng, FH; Ng, WF; Wong, SY, 1998)	2.15

Actions

Excerpt	Reference	Relevance
"Simethicone is used to enhance visualization during colonoscopy."	( Optimal Timing of Simethicone Addition for Bowel Preparation Using Polyethylene Glycol Plus Ascorbic Acid. Goong, HJ; Jeon, SR; Jung, YH; Kim, H; Kim, HG; Ko, BM; Lee, MS, 2019)	1.57

Treatment

Excerpt	Reference	Relevance
"Treatment with simethicone and placebo in double blind crossover fashion."	( Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. Irons, TG; Metcalf, TJ; Sher, LD; Young, PC, 1994)	2.08

Toxicity

Excerpt	Reference	Relevance
" In acute and chronic experiments on 5 species of laboratory animals it was shown that polymethylsiloxane had no general toxic action on the animals, no damaging action on their internal organs, did not affect their functions and the state of the biological fluids, had no pyrogenic or allergenic effect."	( [Study of general toxic properties and side effects of polymethylsiloxane and gentamicin immobilized on it]. Cherviak, PI; Kaban, AP; Keĭsevich, LV; Samodumova, IM; Znamenskiĭ, VA, 1988)	0.27
"Of the 14 adverse events in 11 patients, only five, which included mild diarrhea and nausea, were considered related to the contrast agent."	( Safety and efficacy of a new oral contrast agent for sonography: a phase II trial. Barone, AE; Chong, WK; Goldberg, BB; Langer, JE; Lev-Toaff, AS; Rubin, DL; Zelch, JV, 1999)	0.3
"SonoRx is a safe and well-tolerated contrast agent that improves the sonographic evaluation of the upper abdomen, with significant improvement in imaging the stomach, duodenum, and pancreas."	( Safety and efficacy of a new oral contrast agent for sonography: a phase II trial. Barone, AE; Chong, WK; Goldberg, BB; Langer, JE; Lev-Toaff, AS; Rubin, DL; Zelch, JV, 1999)	0.3
" Dimethicone, Methicone, and Vinyldimethicone were not acutely toxic following oral exposure."	( Final report on the safety assessment of stearoxy dimethicone, dimethicone, methicone, amino bispropyl dimethicone, aminopropyl dimethicone, amodimethicone, amodimethicone hydroxystearate, behenoxy dimethicone, C24-28 alkyl methicone, C30-45 alkyl methico Nair, B, 2003)	0.32

Pharmacokinetics

Excerpt	Reference	Relevance
" Pharmacodynamic parameters were measured for 96 hours."	( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate]. Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G, )	0.13
" The kinetic parameters measured were area under the concentration (AUC), maximum peak plasma concentration (Cmax), time to reach peak concentration (tmax), elimination half-life (t1/2), mean residence time (MRT) and urinary excretion for R and S enantiomers."	( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen. Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998)	0.3
"Dimethicone reduced the peak concentration of both R and S ketoprofen by about 10% (P<0."	( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen. Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998)	0.3
" As a part of the fixed-dose combination registration process in Mexico, a pharmacokinetic and relative bioavailability study was carried out to demonstrate nonexistence of pharmacokinetic interaction when mosapride is administered alone or in combination with pancreatin and simethicone using DOSIER® (mosapride) 5-mg tablets as a reference product."	( Relative bioavailability and pharmacokinetic comparison of a fixed-dose combination tablet of mosapride, pancreatin, and simethicone relative to single-component mosapride tablets in healthy Mexican subjects. Argüelles Tello, FA; Camarillo Cárdenas, KP; García González, J; Moreno Hernández, JB; Ocampo Ramírez, JA; Pendela, MM, 2022)	1.11

Compound-Compound Interactions

Purgative bowel cleansing combined with simethicone before CE improved the quality of imaging of the entire small bowel as well as the visualization of the mucosa in the proximal and distal small intestine. Three days fasting and oral senna, combined with 20% mannitol and simeth silicone, can reduce the effects of bile on the small bowel.

Excerpt	Reference	Relevance
" These parameters were somewhat higher when ceftibuten was administered with ranitidine, but they were still within the ranges seen in normal healthy volunteers."	( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine. Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998)	0.3
"Ninety patients referred for CE were prospectively randomized to three equal groups according to the preparation used: (a) a control group, in which patients were requested to drink 1 L of clear liquids only, 12 h before the examination; (b) a purgative group, in which patients were requested to ingest 1 L of a polyethylene glycol (PEG)/electrolyte solution only, 12 h before the examination; or (c) a purgative combined with simethicone group (P-S group), in which patients were requested to ingest 1 L of PEG, 12 h before the examination, and 300 mg of simethicone, 20 min before the examination."	( Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Gao, YJ; Ge, ZZ; Hu, YB; Lu, H; Wei, W; Xiao, SD, 2008)	0.78
"Purgative bowel cleansing combined with simethicone before CE improved the quality of imaging of the entire small bowel as well as the visualization of the mucosa in the proximal and distal small intestine."	( Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Gao, YJ; Ge, ZZ; Hu, YB; Lu, H; Wei, W; Xiao, SD, 2008)	0.88
"Three days fasting and oral senna, combined with 20% mannitol and simethicone, before CE, can reduce the effects of bile on the small bowel and improve small bowel cleansing, especially in the distal small intestine."	( Randomized controlled trial of 3 days fasting and oral senna, combined with mannitol and simethicone, before capsule endoscopy. Chen, HB; Chun, H; Lian-Xiang, P; Rong-Pang, L; Shu-Ping, X; Xiao-Lin, L; Xiao-Zong, W; Yue, H, 2017)	0.91

Bioavailability

Excerpt	Reference	Relevance
"The aim of the study was to compare the bioavailability of progesterone dissolved in almond oil or dimethicone, and administered by nasal spray."	( Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. Cagnazzo, I; Cicinelli, E; Galantino, P; Savino, F; Scorcia, P, 1992)	0.28
" The bioavailability of cimetidine was not significantly affected by metoclopramide and it was marginally reduced by the antacid."	( Effects on cimetidine bioavailability of metoclopramide and antacids given two hours apart. Barzaghi, N; Crema, F; Mescoli, G; Perucca, E, 1989)	0.28
"The effect of two antacids on the bioavailability of paracetamol has been investigated in 12 young healthy volunteers."	( Effect of two antacids on the bioavailability of paracetamol. Albin, H; Bedjaoui, A; Begaud, B; Demotes-Mainard, F; Vinçon, G, 1985)	0.27
"To investigate the effect of antacid on the bioavailability and disposition of ranitidine six healthy volunteers were studied on two occasions one week apart."	( High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Jones, DB; Louis, WJ; Marino, AT; Mihaly, GW; Smallwood, RA; Webster, LK, 1982)	0.26
" 2 The bioavailability of phenytoin when given concomitantly with Asilone was decreased in five of six volunteer subjects (by greater than 30% in three subjects) although this decrease was not shown to be statistically significant."	( The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Collier, PS; McElnay, JC; Uprichard, G, 1982)	0.26
"The effect of Mylanta on naproxen bioavailability was studied in 11 healthy volunteers."	( Effect of Mylanta on naproxen bioavailability. Bankhurst, AD; Ding, TL; Mroszczak, E; Weber, SS, 1981)	0.26
" The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question."	( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate]. Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G, )	0.13
" However, this treatment had no significant effect on the bioavailability and the elimination of R and S enantiomers, as shown by AUC, t1/2 and MRT values."	( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen. Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998)	0.3
" Dimethicone did not significantly alter the bioavailability of ketoprofen, chosen as an example of an NSAID, especially that of the pharmacologically active S enantiomer."	( Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen. Bannwarth, B; Gillet, P; Herrmann, MA; Lapicque, F; Netter, P; Presle, N, 1998)	0.3
" Bioavailability parameters, maximum plasma concentration and area under the plasma concentration-time curve to infinity of ceftibuten were unaffected by treatment with antacid."	( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine. Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998)	0.3
" As a part of the fixed-dose combination registration process in Mexico, a pharmacokinetic and relative bioavailability study was carried out to demonstrate nonexistence of pharmacokinetic interaction when mosapride is administered alone or in combination with pancreatin and simethicone using DOSIER® (mosapride) 5-mg tablets as a reference product."	( Relative bioavailability and pharmacokinetic comparison of a fixed-dose combination tablet of mosapride, pancreatin, and simethicone relative to single-component mosapride tablets in healthy Mexican subjects. Argüelles Tello, FA; Camarillo Cárdenas, KP; García González, J; Moreno Hernández, JB; Ocampo Ramírez, JA; Pendela, MM, 2022)	1.11

Dosage Studied

The combination of simethicone plus Colyte administered the night before colonoscopy improves visibility by diminishing bubbles. The method can be found in the USP monographs for several dosage forms of Simethicone-containing pharmaceutical products.

Excerpt	Relevance	Reference
" These data indicate that (a) the combination of simethicone plus Colyte administered the night before colonoscopy improves visibility by diminishing bubbles; (b) this dosage of simethicone is not effective in diminishing haziness when administered the night before colonoscopy; and (c) patients with diverticulosis are likely to have feculent debris in the rectosigmoid colon, and a precolonoscopy enema may be helpful when the diagnosis is known."	( The effect of simethicone on colonic visibility after night-prior colonic lavage. A double-blind randomized study. Maydonovitch, CL; McNally, PR; Wong, RK, 1989)	0.89
"A long-acting dosage form for local use of gentamicin immobilized on polymethylsiloxane, a silicon organic adsorbent was developed."	( [Study of general toxic properties and side effects of polymethylsiloxane and gentamicin immobilized on it]. Cherviak, PI; Kaban, AP; Keĭsevich, LV; Samodumova, IM; Znamenskiĭ, VA, 1988)	0.27
" This is possibly due to a higher dosage of dimethycon in Paractol."	( [Premedication for abdominal sonography--comparison of the efficacy of 2 dimethicone preparations]. Elfner, R; Gladisch, R; Massner, B; Ulrich, H, 1985)	0.27
"5 micrograms/ml were maintained for the entire dosing interval in seven of 10 subjects."	( Effect of antacids on predicted steady-state cimetidine concentrations. Doering, PL; Guild, RT; Lopez, LM; Normann, SA; Russell, WL, 1984)	0.27
"Over a 15-month period, 75 critically ill patients at risk of acute gastrointestinal bleeding were randomized into two groups: one group (38 patients) received the H2-blocker cimetidine intravenously at an initial dosage of 300 mg every six hours, and the other group (37 patients) received antacid (Mylanta II) through a nasogastric tube at an intial dosage of 30 ml every hour."	( Antacid versus cimetidine in preventing acute gastrointestinal bleeding. A randomized trial in 75 critically ill patients. Bushnell, LS; Long, PC; Priebe, HJ; Silen, W; Skillman, JJ, 1980)	0.26
" Twice a day dosage is likely to improve patient compliance, costs less, and may reduce dose-related side effects."	( Twice-a-day dosage of cimetidine in the short-term treatment of peptic ulcer. Eaves, R; Korman, MG, 1982)	0.26
" The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question."	( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate]. Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G, )	0.13
" No adverse reactions were found in rabbits following short-term dermal dosing with 6% to 79% Dimethicone, yet adverse effects were noted with a hand cream formulation containing 1% Dimethicone, suggesting something else in the preparation was toxic."	( Final report on the safety assessment of stearoxy dimethicone, dimethicone, methicone, amino bispropyl dimethicone, aminopropyl dimethicone, amodimethicone, amodimethicone hydroxystearate, behenoxy dimethicone, C24-28 alkyl methicone, C30-45 alkyl methico Nair, B, 2003)	0.32
" The method can be found in the USP monographs for several dosage forms of Simethicone-containing pharmaceutical products."	( Improvements in soft gelatin capsule sample preparation for USP-based simethicone FTIR analysis. Hargis, AD; Whittall, LB, 2013)	0.85
" However, the optimal dose, volume, and dosing time for the premedication regimen are still unclear."	( Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy. Chang, WK; Chen, HW; Hsu, HC; Hu, MK; Yeh, MK, 2014)	0.78
" Utilizing a 90-day BUD, lidocaine can be packaged separately from other magic mouthwash ingredients in individual dosage units and applied to the oral cavity using the swish-and-spit method."	( Beyond-use dating of lidocaine alone and in two "magic mouthwash" preparations. Brown, SD; Huffman, J; Kirk, LM; Lewis, PO; Luu, Y; Ogle, A, 2017)	0.46
" After 10 s, photographs were taken and the visible bubbles were semi-quantitatively rated by independent assessors blinded to the dosing of simethicone."	( An in vitro and clinical dose-finding study of antifoaming effects of simethicone during colonoscopy. Elson, J; Holtmann, GJ; Hourigan, LF; Kutyla, MJ; Meeusen, V; O'Connor, S; Shah, A, 2019)	0.95
" The rate of total BBPS score ≥6 remained significantly higher in the SIM group when a single-dose laxative regimen or a SIM dosage of ≥320 mg was employed; and ADR, PDR and CIR were significantly increased in the SIM group among colonoscopy clinicians who achieved an ADR <31%, PDR <45% and CIR <96%, respectively."	( Effect of oral simethicone on the quality of colonoscopy: A systematic review and meta-analysis of randomized controlled trials. Cao, RR; Gao, C; Li, HY; Pan, JH; Qi, XS; Wang, L; Yoshida, EM, 2022)	1.07
"Oral SIM can improve bowel preparation quality, especially in patients receiving a SIM dosage of ≥320 mg or a single-dose laxative regimen."	( Effect of oral simethicone on the quality of colonoscopy: A systematic review and meta-analysis of randomized controlled trials. Cao, RR; Gao, C; Li, HY; Pan, JH; Qi, XS; Wang, L; Yoshida, EM, 2022)	1.07

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Products

Product Category	Products
Other	4
Alimentos e bebidas à base de plantas,Alimentos à base de plantas,Gorduras,Gorduras vegetals,Produtos de oliveira,Olios vegetais,Azeite de oliva,Azeites virgem extra	1
Condiments, Sauces, Sauces samouraï	1
en:stuffed-pastas	1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Condiments, Epices, Poivres, Poivres noirs, Poivres moulus, Poivre noir moulu, en:groceries	1
Beauty & Personal Care	19

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Good Clean Love Rebalance Moisturizing & Cleansing Wipes -- 30 Wipes	Good Clean Love	Beauty & Personal Care	goldenseal, gluconic acid, lactic acid, propanediol, simethicone, sodium benzoate	2024-11-29 10:47:42
Good Clean Love Rebalance Personal Moisturizing & Cleansing Wipes -- 12 Wipes	Good Clean Love	Beauty & Personal Care	goldenseal, gluconic acid, lactic acid, propanediol, simethicone, sodium benzoate	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 10C Swedish Blonde -- 135 mL	Herbatint	Beauty & Personal Care	isopropyl alcohol, citric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 2N Brown -- 135 mL	Herbatint	Beauty & Personal Care	citric acid, p-phenylenediamine, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 3N Dark Chestnut -- 135 mL	Herbatint	Beauty & Personal Care	isopropyl alcohol, P-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, propylene glycol, simethicone, sodium benzoate	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4M Mahogany Chestnut -- 135 mL	Herbatint	Beauty & Personal Care	2-amino-3-hydroxypyridine, m-aminophenol, p-aminophenol, p-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, methyl benzoate, propylene glycol, simethicone	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4N Chestnut -- 135 mL	Herbatint	Beauty & Personal Care	p-phenylenediamine, cetyl alcohol, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 5N Light Chestnut -- 135 mL	Herbatint	Beauty & Personal Care	p-phenylenediamine, ethanolamine, oleic acid, propylene glycol, simethicone, sodium metabisulfite	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 6N Dark Blonde -- 135 mL	Herbatint	Beauty & Personal Care	citric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate, sodium metabisulfite	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 7N Blonde -- 135 mL	Herbatint	Beauty & Personal Care	isopropyl alcohol, citric acid, p-phenylenediamine, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium metabisulfite	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 8N Light Blonde -- 135 mL	Herbatint	Beauty & Personal Care	isopropyl alcohol, citric acid, cetyl alcohol, citric acid, ethanolamine, etidronic acid, imidazolidinyl urea, oleic acid, propylene glycol, simethicone, sodium benzoate	2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 9N Honey Blonde -- 135 mL	Herbatint	Beauty & Personal Care	isopropyl alcohol, citric acid, p-phenylenediamine, cetyl alcohol, citric acid, etidronic acid, oleic acid, propylene glycol, simethicone, sodium metabisulfite	2024-11-29 10:47:42
MyChelle Dermaceuticals Protect Sun Shield Sunscreen SPF 28 Coconut -- 2.3 fl oz	MyChelle Dermaceuticals	Beauty & Personal Care	allantoin, cetearyl alcohol, glycerin, simethicone, squalane, Titanium Dioxide	2024-11-29 10:47:42
Vanicream Cleansing Bar Soap Fragrance Free -- 3.9 oz	Vanicream	Beauty & Personal Care	cetearyl alcohol, glyceryl stearate, propanediol, sodium lauroyl sarcosinate, simethicone, sorbitol, stearic acid	2024-11-29 10:47:42
Vanicream HC 1% Hydrocortizone Anti-Itch Cream For Sensitive Skin -- 2 oz	Vanicream	Beauty & Personal Care	cetearyl alcohol, glyceryl stearate, propanediol, simethicone, sorbic acid	2024-11-29 10:47:42
Vanicream Moisturizing Cream -- 16 oz	Vanicream	Beauty & Personal Care	cetearyl alcohol, glyceryl stearate, propylene glycol, simethicone, sorbic acid, sorbitol	2024-11-29 10:47:42
Vanicream Moisturizing Cream For Sensitive Skin Travel Tube -- 2 fl oz	Vanicream	Beauty & Personal Care	BHT, cetearyl alcohol, glyceryl stearate, propylene glycol, simethicone, sorbic acid, sorbitol	2024-11-29 10:47:42
Vanicream Moisturizing Lotion -- 16 fl oz	Vanicream	Beauty & Personal Care	cetearyl alcohol, glyceryl stearate, propylene glycol, simethicone, sorbic acid, sorbitol	2024-11-29 10:47:42
Vanicream Moisturizing Skin Cream with Pump Dispenser Fragrance Free -- 16 oz	Vanicream	Beauty & Personal Care	cetearyl alcohol, glyceryl stearate, propylene glycol, simethicone, sorbic acid	2024-11-29 10:47:42

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	108 (29.67)	18.7374
1990's	65 (17.86)	18.2507
2000's	62 (17.03)	29.6817
2010's	95 (26.10)	24.3611
2020's	34 (9.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	167 (42.17%)	5.53%
Reviews	35 (8.84%)	6.00%
Case Studies	26 (6.57%)	4.05%
Observational	1 (0.25%)	0.25%
Other	167 (42.17%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (49)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effects of Moviprep With Simethicone on Colonic Bubbles [NCT01209806]		140 participants (Actual)	Interventional	2009-11-30	Completed
Optimization of Simethicone Administration Strategy Before Esophagogastroscopy [NCT03776916]		311 participants (Actual)	Interventional	2019-05-01	Completed
Multicenter, Randomized, Parallel-group, Open-label, Comparative Clinical Study to Evaluate Efficacy and Safety of Mebeverine+Simethicone Fixed-dose Combination Versus Duspatalin® (Mebeverine) and Versus Espumisan® (Simethicone) in Patients With Functiona [NCT05175131]	Phase 3	465 participants (Actual)	Interventional	2020-11-27	Completed
Effects of Simethicone and Vivatlac Baby in Infantile Colic [NCT04487834]	Phase 2	87 participants (Actual)	Interventional	2020-04-16	Completed
Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy: a Prospective Randomized Controlled Study [NCT03662113]		200 participants (Actual)	Interventional	2017-11-01	Completed
Effect of Simethicone on Reducing Bowel Interference During Minilaparotomy for Tubal Resection : a Randomized Controlled Trial [NCT03429621]	Phase 3	120 participants (Actual)	Interventional	2018-03-08	Completed
Simethicone Pretreatment With Low-volume Polyethylene Glycol-3350 and Bisacodyl in an Effort to Improve Bowel Wall Visualization During Colonoscopy [NCT03410524]	Phase 3	250 participants (Actual)	Interventional	2018-01-09	Completed
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain [NCT01269671]	Phase 1	0 participants (Actual)	Interventional	2011-01-31	Withdrawn(stopped due to PI has left institution)
Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study [NCT03166605]		36 participants (Anticipated)	Interventional	2017-05-03	Recruiting
A Randomized Controlled Trial of the Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery: A Pilot Study [NCT02161367]	Phase 4	100 participants (Actual)	Interventional	2014-10-31	Completed
Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate Bowel Preparation With and Without Simethicone for Routine Colonoscopy: A Double-blinded Randomized Controlled Trial [NCT02523911]		0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to investigator graduated and is not longer at this institution)
Use of Simethicone to Improve the Bowel Cleansing Effects of Polyethylene Glycol With Ascorbic Acid for Colonoscopy [NCT02548403]	Phase 3	260 participants (Actual)	Interventional	2014-07-31	Completed
A Relative Bioavailability Study of Loperamide HCl 2 mg and Simethicone 125 mg Tablets to Imodium® Advanced Caplets Under Fasting Condition [NCT00778115]		26 participants (Actual)	Interventional	2004-11-30	Completed
[NCT02540239]		590 participants (Actual)	Interventional	2015-01-31	Completed
An Open-Label, 3-Period, Fixed-Sequence, Study to Examine the Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects [NCT04368585]	Phase 1	20 participants (Actual)	Interventional	2020-07-01	Completed
Pre-medication With N-acetylcysteine and Simethicone to Improve Mucosal Visibility During Gastroduodenoscopy: A Double Blind, Randomized Controlled Trial. [NCT05951712]		800 participants (Actual)	Interventional	2022-06-16	Completed
A Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Appropriateness of Multiple Endpoints in Measuring the Onset of Clinical Efficacy of Loperamide-Simethicone Caplets in the Treatment of Acute Non-specific Diarrhea [NCT00685607]	Phase 4	45 participants (Actual)	Interventional	2008-10-31	Completed
Efficacy of Fixed-dose Combination of Bromopride and Simethicone Versus Isolated Bromopride in Participants With Functional Dyspepsia. [NCT02604576]	Phase 3	339 participants (Actual)	Interventional	2017-01-17	Completed
A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics [NCT00679302]	Phase 4	161 participants (Actual)	Interventional	2006-07-31	Completed
The Effectiveness of Simethicone In Improving Visibility During Colonoscopy: A Randomized, Placebo-controlled Study [NCT00615303]	Phase 4	194 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults [NCT00807326]	Phase 4	415 participants (Actual)	Interventional	2008-11-30	Completed
Effects of Simethicone and Multilac Baby on Fecal Calprotectin Levels Infantile Colic [NCT04666324]		100 participants (Anticipated)	Interventional	2020-12-31	Not yet recruiting
Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study [NCT01984931]	Phase 3	45 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A Pilot Study of the Effect of Simethicone in Adult Subjects With a Common Cold on Eustachian Tube Dysfunction [NCT01312038]	Phase 2	25 participants (Actual)	Interventional	2011-03-31	Completed
An Open-label, Randomized, Fasting, Two-period, Single-dose, Crossover Study to Assess Bioequivalence Between a Combination Caplet With Loperamide Hydrochloride and Simethicone (Janssen-Cilag, France), and Imodium® Express Tablets-lyophilizate (Janssen-Ci [NCT04186936]	Phase 1	48 participants (Actual)	Interventional	2019-12-05	Completed
Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial [NCT02846155]	Phase 2	120 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Assessment of Combined Bowel Preparation for Capsule Endoscopy Study [NCT01243736]	Phase 1	50 participants (Actual)	Interventional	2010-04-30	Completed
Comparison of Low-volume Versus High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis: a Randomized Non-inferiority Trial [NCT04709770]	Phase 4	264 participants (Anticipated)	Interventional	2021-02-01	Not yet recruiting
The Impact of Air Travel on Passenger Cognitive Functions [NCT04802785]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
Effect of Adding Simethicone to a Split Regimen of Polyethylene Glycol for Bowel Preparation in a Colorectal Cancer Screening Colonoscopy Setting: an Endoscopist-blinded Randomized Controlled Trial [NCT03816774]		412 participants (Actual)	Interventional	2019-06-15	Completed
Efficacy of a Standardized Extract of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) Compared With Lactobacillus Reuteri (DSM 17938) and With Simethicone for the Treatment of Infantile Colic [NCT02708238]	Phase 4	180 participants (Actual)	Interventional	2014-04-30	Completed
Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. [NCT01653171]	Phase 4	230 participants (Actual)	Interventional	2012-07-31	Completed
Simethicone and Gynecological Laparoscopies: Does it Improve Operative Field and Postoperative Pain? [NCT02984176]	Phase 4	100 participants (Actual)	Interventional	2014-08-31	Completed
EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN [NCT01711437]	Phase 4	400 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico [NCT04145856]	Phase 4	55 participants (Actual)	Interventional	2018-09-03	Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adult Subjects [NCT05109390]	Phase 1	72 participants (Actual)	Interventional	2018-07-27	Completed
Evaluation of Two Different Regimens of Colon Preparations for Advanced Cleaning Using a 2lt PEG-CS With Simethicone: a Randomized Controlled Study. [NCT05570669]	Phase 4	321 participants (Actual)	Interventional	2021-05-25	Completed
Nutritional Intervention, Multicenter, Randomized, Blind, Parallel Groups Study to Assess the Effect of Consumption of Bifidobacterium Breve CECT7263 and Lactobacillus Fermentum CECT5716 on Infant Colic [NCT03467334]	Phase 2	156 participants (Actual)	Interventional	2017-05-31	Completed
[NCT03009604]	Phase 3	90 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Benefits of Premedication With Small Volume Simethicone Solution Before Diagnostic Gastroscopy: A Randomized Endoscopist-blinded Prospective Study [NCT02555228]	Phase 2/Phase 3	54 participants (Actual)	Interventional	2015-08-31	Completed
The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial [NCT03119168]	Phase 4	268 participants (Actual)	Interventional	2017-03-15	Completed
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles [NCT01790139]		84 participants (Actual)	Interventional	2013-02-28	Completed
Comparison Between Asymmetric (Low Dose In The Morning) And Standard Split-Dose Regimen Of Polyethylene Glycol Plus Bisacodyl For Bowel Preparation For Screening And Surveillance Colonoscopy: A Randomized Non-Inferiority Clinical Trial. [NCT03146052]		81 participants (Actual)	Interventional	2017-03-27	Completed
Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial [NCT02357303]	Phase 4	300 participants (Actual)	Interventional	2015-04-30	Completed
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION Trial): Protocol of a Multicentre Randomized Controlled Clinical Trial [NCT05100719]		200 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Loperamide Hydrochloride/Simethicone Chewable Tablet in the Treatment of Acute Diarrhea With Abdominal Discomfort and Flat [NCT02340481]	Phase 3	217 participants (Actual)	Interventional	2005-07-31	Completed
A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy [NCT02334631]	Phase 4	159 participants (Actual)	Interventional	2017-01-31	Completed
Addition of Oral Simethicone to Bowel Preparation in Colonoscopy [NCT03157791]	Phase 4	471 participants (Actual)	Interventional	2017-07-05	Completed
A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration [NCT02217982]	Phase 4	5 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Study did not meet required enrollment numbers)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00679302 (2) [back to overview]	New Lesion Development and Spread of Skin Abscesses (on Subject)
NCT00679302 (2) [back to overview]	Skin Abscess Resolution
NCT01312038 (1) [back to overview]	Fraction of Middle Ear (ME) Pressure Equilibrated (FGE)
NCT02217982 (2) [back to overview]	Diarrhea Reduction
NCT02217982 (2) [back to overview]	Reported GI Symptoms
NCT02555228 (4) [back to overview]	Adverse Events in Each Group Which May or May Not be Related to Simethicone Solution
NCT02555228 (4) [back to overview]	Total Cumulative Mucosal Visibility Score
NCT02555228 (4) [back to overview]	Volume of Additional Manual Flushes Required During Endoscopy in Mls
NCT02555228 (4) [back to overview]	Mucosal Visibility Score Per Area as Determined by Mc Nally Score:
NCT02708238 (2) [back to overview]	Median Daily Crying Time at the End of the Treatment
NCT02708238 (2) [back to overview]	Number of Responders
NCT03119168 (4) [back to overview]	Adenoma Detection Rate
NCT03119168 (4) [back to overview]	Intraprocedural Use of Simethicone
NCT03119168 (4) [back to overview]	Withdrawal Times
NCT03119168 (4) [back to overview]	Colon Preparation
NCT04487834 (3) [back to overview]	Number of Participants With a Reduction of Average Duration of Evening Crying Equal or More Than 50 Percent
NCT04487834 (3) [back to overview]	Number of Participants With a Reduction of Average Number of Crying Phases Per Day Equal or More Than 50 Percent
NCT04487834 (3) [back to overview]	Number of Participants With a Reduction of Days Crying Equal or More Than 50 Percent From Baseline

New Lesion Development and Spread of Skin Abscesses (on Subject)

The secondary outcomes of interest included the development of new lesions at a different site (>5cm away from original skin abscess) on day 10 clinical follow-up or self-report and 3 month telephone follow-up. (NCT00679302)
Timeframe: 10-14 days and 3 month

Intervention	participants (Number)
Placebo Group	15
Antibiotic Group	13

Intervention	ratio (Mean)
	Pre treatment FGE at -200 daPa	post-treatment FGE at -200 daPa	Pre -treatment FGE at 200 daPa	Post-treatment FGE at 200 daPa
Placebo	0.24	0.23	0.30	0.34
Simethicone-treated	0.17	0.19	0.24	0.24

Intervention	units on a scale (Mean)
	Area E (esopahgus)	Area D (duodenum)	Area A (antrum and angularis)	Area B (body and fundus)
Placebo	1.59	2.26	2.56	2.44
Simethicone Premedication	1.48	1.26	1.30	1.74

Intervention	adenomas (Number)
Simethicone Solution + Polyethylenglycol	43
Polyethylenglycol	54

Intervention	seconds (Mean)
Simethicone Solution + Polyethylenglycol	395.7
Polyethylenglycol	399

Intervention	score on a scale (Mean)
	Boston Bowel Preparation Scale	Bubble Scale
Polyethylenglycol	8.9	2.1
Simethicone Solution + Polyethylenglycol	8.9	0.1

Substance	Relationship Strength	Studies	Trials	Classes	Roles
allantoin [no description available]	3.35	1	1	imidazolidine-2,4-dione; ureas	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite; vulnerary
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	10.32	19	10	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.41	2	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	3.79	2	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	5.65	7	3	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	5.45	4	4	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	4.33	1	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
phenytoin [no description available]	1.96	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.39	2	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	3.4	1	1	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	9.1	9	7	diarylmethane
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	7.69	17	11	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cisapride Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.	5.81	6	4	benzamides
clotrimazole [no description available]	1.96	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
dibutyl phthalate Dibutyl Phthalate: A plasticizer used in most plastics and found in water, air, soil, plants and animals. It may have some adverse effects with long-term exposure.. dibutyl phthalate : A phthalate ester that is the diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol. Although used extensively as a plasticiser, it is a ubiquitous environmental contaminant that poses a risk to humans.	1.98	1	0	diester; phthalate ester	EC 3.2.1.20 (alpha-glucosidase) inhibitor; environmental contaminant; metabolite; plasticiser; teratogenic agent
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	7.71	9	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	3.06	1	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	1.95	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	3.45	1	1	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
famotidine Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.	10.21	4	3	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
gabexate Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.	1.99	1	0	benzoate ester
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	2.66	3	0
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	1.96	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	3.78	2	1	methoxybenzenes
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	3.35	1	1	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	6.04	3	2	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
alverine alverine : A tertiary amine having one ethyl and two 3-phenylprop-1-yl groups attached to the nitrogen. An antispasmodic that acts directly on intestinal and uterine smooth muscle, it is used (particularly as the citrate salt) in the treatment of irritable bowel syndrome.	7.6	7	5	tertiary amine	antispasmodic drug
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.96	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	9.41	1	1	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	1.99	1	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	3.38	1	1	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	8.02	6	5	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	6.71	6	4	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	4.38	2	2	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	3.35	1	1	dichlorobenzene; ether; imidazoles
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	5.07	3	3	aromatic ether; benzimidazoles; pyridines; sulfoxide
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	4.43	2	2	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.4	1	1	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	6.13	3	2	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.6	1	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative

Condition	Relationship Strength	Studies	Trials
Colorectal Cancer [description not available]	13.77	21	15
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	13.77	21	15
Cancer of Prostate [description not available]	3.8	1	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.8	1	1
Adenoma, Basal Cell [description not available]	14.9	28	19
Adenoma A benign epithelial tumor with a glandular organization.	14.9	28	19
Fasciitis, Necrotizing A fulminating bacterial infection of the deep layers of the skin and FASCIA. It can be caused by many different organisms, with STREPTOCOCCUS PYOGENES being the most common.	2.6	1	0
Endotoxin Shock [description not available]	2.6	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	2.6	1	0
Cancer of Colon [description not available]	12.62	16	14
Colonic Neoplasms Tumors or cancer of the COLON.	12.62	16	14
Complication, Postoperative [description not available]	7.02	13	7
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	7.02	13	7
Abdominal Cramps [description not available]	17.86	68	44
Neglected Diseases Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).	2.25	1	0
Infections, Nematomorpha [description not available]	2.25	1	0
Schistosoma haematobia Infection [description not available]	2.25	1	0
Helminthiasis Infestation with parasitic worms of the helminth class.	2.25	1	0
Schistosomiasis haematobia A human disease caused by the infection of parasitic worms SCHISTOSOMA HAEMATOBIUM. It is endemic in AFRICA and parts of the MIDDLE EAST. Tissue damages most often occur in the URINARY TRACT, specifically the URINARY BLADDER.	2.25	1	0
Gout Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.	2.31	1	0
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	7.17	8	5
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	7.17	8	5
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.62	1	1
Cholera Infantum [description not available]	9.02	11	6
Benign Neoplasms [description not available]	3.32	2	0
Mucositis, Oral [description not available]	3.06	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.32	2	0
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	3.06	1	0
Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.	7.29	6	3
Bacterial Disease [description not available]	3.53	1	1
Bowel Incontinence [description not available]	4.41	2	2
Flatus [description not available]	8.46	15	4
Bacterial Infections Infections by bacteria, general or unspecified.	3.53	1	1
Fecal Incontinence Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus.	4.41	2	2
Flatulence Production or presence of gas in the gastrointestinal tract which may be expelled through the anus.	8.46	15	4
Cancer of Stomach [description not available]	4.49	2	2
Stomach Neoplasms Tumors or cancer of the STOMACH.	4.49	2	2
Gastric Diseases [description not available]	11.12	13	10
Cancer of Gastrointestinal Tract [description not available]	3.56	1	1
Condition, Preneoplastic [description not available]	3.56	1	1

simethicone

Description

Cross-References

Synonyms (8)

Research Excerpts

Overview

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (27 Product(s))

Product Categories

Products

Research

Studies (364)

Study Types

Clinical Trials (49)

Trial Overview

Trial Outcomes

New Lesion Development and Spread of Skin Abscesses (on Subject)

Skin Abscess Resolution

Fraction of Middle Ear (ME) Pressure Equilibrated (FGE)

Diarrhea Reduction

Reported GI Symptoms

Adverse Events in Each Group Which May or May Not be Related to Simethicone Solution

Total Cumulative Mucosal Visibility Score

Volume of Additional Manual Flushes Required During Endoscopy in Mls

Mucosal Visibility Score Per Area as Determined by Mc Nally Score:

Median Daily Crying Time at the End of the Treatment

Number of Responders

Adenoma Detection Rate

Intraprocedural Use of Simethicone

Withdrawal Times

Colon Preparation

Number of Participants With a Reduction of Average Duration of Evening Crying Equal or More Than 50 Percent

Number of Participants With a Reduction of Average Number of Crying Phases Per Day Equal or More Than 50 Percent

Number of Participants With a Reduction of Days Crying Equal or More Than 50 Percent From Baseline

Related Drugs (142)

Related Conditions (290)